Development of bifeprunox for maintenance treatment of schizophrenia discontinued
Lundbeck and Solvay have announced that they are discontinuing development of bifeprunox for the maintenance treatment of schizophrenia.
Lundbeck and Solvay have announced that they are discontinuing development of bifeprunox for the maintenance treatment of schizophrenia.
After analyzing results from an interim analysis of pooled data, the companies decided that the efficacy data did not support continued development of this agent for the stabilization of nonacute schizophrenia.
FDA issued a nonapprovable letter for bifeprunox for the acute and maintenance treatment of schizophrenia in August 2007. In its letter, FDA stated that a second study would be needed to support the approval of bifeprunox for the maintenance treatment of schizophrenia. The agency also stated that the efficacy data were not sufficient for the approval of bifeprunox for the acute treatment of schizophrenia.
FDA Clears Phase 2 Trial of Cannabis in PTSD
November 20th 2024After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.
Read More
